NIKKEI 225
28,864.320.00(0.00%)HANG SENG
29,098.29-138.51(-0.47%)CRUDE OIL
67.15+1.06(+1.60%)
GlaxoSmithKline plc (GSK.L)
| Previous close | 1,224.20 |
| Open | 1,212.40 |
| Bid | 1,225.60 x 0 |
| Ask | 1,250.00 x 0 |
| Day's range | 1,210.80 - 1,247.00 |
| 52-week range | 1,190.80 - 1,772.51 |
| Volume | 9,846,843 |
| Avg. volume | 10,424,329 |
| Market cap | 62.536B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | 10.89 |
| EPS (TTM) | 114.10 |
| Earnings date | 28 Apr 2021 |
| Forward dividend & yield | 0.80 (6.44%) |
| Ex-dividend date | 18 Feb 2021 |
| 1y target est | 1,644.50 |
- Motley Fool
After 2 Licensing Deals Will GlaxoSmithKline Acquire Vir?
Vir Biotechnolgy (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) recently expanded their partnership from a single drug to treat COVID-19 to a multi-drug partnership that covers a drug for the flu, as well as drugs that Vir hasn't even developed yet.
- Motley Fool
Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to Flu
Last year, Vir Biotechnology (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) partnered up to develop Vir's coronavirus antibody treatment. The London-based pharma must have liked what it saw in Vir, because GlaxoSmithKline recently signed on to develop more drugs developed by Vir. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the deal, which covers treatments and preventions for the flu and other viral infections, and what it means for Vir's future.
- Motley Fool
Will Sanofi and GlaxoSmithKline Be Too Late to the Party With Their COVID Vaccine?
Johnson & Johnson (NYSE: JNJ) recently won U.S. Emergency Use Authorization (EUA) for its vaccine. In this Motley Fool Live video, recorded on Feb. 24, Fool.com contributors Keith Speights and Brian Orelli discuss whether or not Sanofi and GlaxoSmithKline might be too late to the party.
